0001752724-23-276835.txt : 20231212 0001752724-23-276835.hdr.sgml : 20231212 20231212105322 ACCESSION NUMBER: 0001752724-23-276835 CONFORMED SUBMISSION TYPE: N-CEN PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231212 DATE AS OF CHANGE: 20231212 EFFECTIVENESS DATE: 20231212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: abrdn World Healthcare Fund CENTRAL INDEX KEY: 0001635977 IRS NUMBER: 000000000 STATE OF INCORPORATION: PA FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: N-CEN SEC ACT: 1940 Act SEC FILE NUMBER: 811-23037 FILM NUMBER: 231480321 BUSINESS ADDRESS: STREET 1: 1900 MARKET STREET STREET 2: SUITE 200 CITY: PHILADELPHIA STATE: PA ZIP: 19103 BUSINESS PHONE: (617) 772-8515 MAIL ADDRESS: STREET 1: 1900 MARKET STREET STREET 2: SUITE 200 CITY: PHILADELPHIA STATE: PA ZIP: 19103 FORMER COMPANY: FORMER CONFORMED NAME: Tekla World Healthcare Fund DATE OF NAME CHANGE: 20150306 N-CEN 1 primary_doc.xml X0404 N-CEN LIVE 0001635977 XXXXXXXX 811-23037 false false false N-2 abrdn World Healthcare Fund 811-23037 0001635977 549300XY2WS5AD8KC081 100 FEDERAL STREET, 19TH FLOOR BOSTON 02110 US-MA US 617-772-8500 State Street Bank and Trust Company 1 Congress Street Suite 1 Boston 02114 617-786-3000 Accounting and Custody Records Tekla Capital Management LLC 100 Federal Street 19th Floor Boston 02110 617-772-8500 Fund Administration Records N N N-2 N Thomas M. Kent, CPA N/A N Rakesh K. Jain, Ph.D. N/A N W. Mark Watson, CPA N/A N Daniel R. Omstead, Ph.D. N/A Y Jeffrey A. Bailey N/A N Kathleen L. Goetz N/A N Laura Woodward, CPA N/A 100 Federal Street, 19th Floor Boston 02110 XXXXXX N N N N N N KPMG LLP 185 5493003PVCIGA21K0K42 Y N N N N abrdn World Healthcare Fund 549300XY2WS5AD8KC081 N 0 0 0 N/A N N Y N N Goldman Sachs Bank USA KD3XUN7C6T14HNAYLU02 N N Revenue sharing split Cash collateral reinvestment fee 1568580.08000000 6488.00000000 Rule 18f-4(e) (17 CFR 270.18f-4(e)) Rule 17a-6 (17 CFR 270.17a-6) Rule 18f-4 (17 CFR 270.18f-4) N N N N Tekla Capital Management LLC 801-61018 000119626 254900YSXGYL9SE8C952 N Computershare Trust Company, National Association 85-11340 2549001YYB62BVMSAO13 N N N Refinitiv US Holdings Inc. 549300NF240HXJO7N016 N ICE Data Services, Inc. 13-3668779 Tax ID N N Royal Bank of Canada ES7IP3U3RHIGC71XBU11 CA N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) BNP Paribas R0MUWSFPU8MPRO8K5P83 FR N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) FirstRand Bank Limited ZAYQDKTCATIXF9OQY690 ZA N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) Bank Hapoalim B.M. B6ARUI4946ST4S7WOU88 IL N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) Citibank, National Association (Singapore, SG, Branch) E57ODZWZ7FF32TWEFA76 SG N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) Deutsche Bank Aktiengesellschaft 7LTWFZYICNSX8D621K86 DE N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) Citibank Europe Public Limited Company N1FBEDJ5J41VKZLO2475 IE N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) UBS Switzerland AG 549300WOIFUSNYH0FL22 CH N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) Banco Nacional de Mexico, S.A., Integrante del Grupo Financiero Banamex 2SFFM4FUIE05S37WFU55 MX N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) State Street Trust Company Canada 549300L71XG2CTQ2V827 CA N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) State Street Bank and Trust Company (Boston, MA, US, Branch) 571474TGEMMWANRLN572 N N Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1)) Clearstream Banking S.A. 549300OL514RA0SXJJ44 LU N Y Foreign securities depository - rule 17f-7 (17 CFR 270.17f-7) Citibank Europe Public Limited Company (Budapest, HU, Branch) N1FBEDJ5J41VKZLO2475 HU N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) The Hongkong and Shanghai Banking Corporation Limited (Sydney, NSW, AU, Branch) 2HI3YI5320L3RW6NJ957 AU N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) State Street Bank and Trust Company (Edinburgh, GB, Branch) 571474TGEMMWANRLN572 GB N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) State Street Bank International GmbH ZMHGNT7ZPKZ3UFZ8EO46 DE N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) The Hongkong and Shanghai Banking Corporation Limited (Chuo ku, Tokyo, JP, Branch) 2HI3YI5320L3RW6NJ957 JP N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) The Hongkong and Shanghai Banking Corporation Limited 2HI3YI5320L3RW6NJ957 HK N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) Ceskoslovenska obchodni banka, a. s. Q5BP2UEQ48R75BOTCB92 CZ N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) Skandinaviska Enskilda Banken A/S F3JS33DEI6XQ4ZBPTN86 DK N Y Foreign custodian - rule 17f-5 (17 CFR 270.17f-5) N Computershare Trust Company, National Association 2549001YYB62BVMSAO13 N N N State Street Bank and Trust Company (Boston, MA, US, Branch) 571474TGEMMWANRLN572 N N N Sanford C. Bernstein & Co., LLC 8-52942 000104474 549300I7JYZHT7D5CO04 2275.09000000 Goldman Sachs & Co. LLC 8-129 000000361 FOR8UP27PHTHYVLBNG30 54725.62000000 J.P. Morgan Securities LLC 8-35008 000000079 ZBUT11V806EZRVTWT807 25286.14000000 RBC Capital Markets, LLC 8-45411 000031194 549300LCO2FLSSVFFR64 2859.72000000 UBS Securities LLC 8-22651 000007654 T6FIZBDPKLYJKFCRVK44 2133.90000000 Nomura Securities International, Inc. 8-15255 000004297 OXTKY6Q8X53C9ILVV871 4973.04000000 National Financial Services LLC 8-26740 000013041 549300JRHF1MHHWUAW04 7027.08000000 BNY Mellon Capital Markets, LLC 8-35255 000017454 VJW2DOOHGDT6PR0ZRO63 15245.40000000 Stifel, Nicolaus & Company, Incorporated 8-1447 000000793 5WUVMA08EYG4KEUPW589 2900.33000000 Jefferies LLC 8-15074 000002347 58PU97L1C0WSRCWADL48 5623.32000000 127121.81000000 Jefferies LLC 8-15074 000002347 58PU97L1C0WSRCWADL48 7963224.90000000 J.P. Morgan Securities LLC 8-35008 000000079 ZBUT11V806EZRVTWT807 135878530.51000000 BNY Mellon Capital Markets, LLC 8-35255 000017454 VJW2DOOHGDT6PR0ZRO63 3354923.17000000 State Street Bank and Trust Company N/A N/A 571474TGEMMWANRLN572 4377907000.00000000 AMOLYT PHARMA N/A N/A N/A 2300648.98000000 European Biotech Acquisition Corp. N/A N/A 984500Y57CDE4CE7CC20 NL 428400.00000000 4527838393.31000000 N 479275876.57000000 Common stock Tekla World Healthcare Fund N N N N N N 1.25000000 2.99000000 11.72000000 11.73000000 true INTERNAL CONTROL RPT 2 NCEN_811-23037_24107182_0923.htm worldhealthcarencen.htm - Generated by SEC Publisher for SEC Filing

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Trustees
abrdn World Healthcare Fund:

In planning and performing our audit of the financial statements of abrdn World Healthcare Fund (formerly, Tekla World Healthcare Fund) (the Fund) as of and for the year ended September 30, 2023, in accordance with the standards of the Public Company Accounting Oversight Board (United States), we considered the Fund's internal control over financial reporting, including controls over safeguarding securities, as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements and to comply with the requirements of Form N-CEN, but not for the purpose of expressing an opinion on the effectiveness of the Fund's internal control over financial reporting. Accordingly, we express no such opinion.

Management of the Fund is responsible for establishing and maintaining effective internal control over financial reporting. In fulfilling this responsibility, estimates and judgments by management are required to assess the expected benefits and related costs of controls. A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

A deficiency in internal control over financial reporting exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis.

Our consideration of the Fund's internal control over financial reporting was for the limited purpose described in the first paragraph and would not necessarily disclose all deficiencies in internal control that might be material weaknesses under standards established by the Public Company Accounting Oversight Board (United States). However, we noted no deficiencies in the Fund's internal control over financial reporting and its operation, including controls over safeguarding securities, that we consider to be a material weakness as defined above as of September 30, 2023.

This report is intended solely for the information and use of the management and the Board of Trustees of abrdn World Healthcare Fund (formerly, Tekla World Healthcare Fund) and the Securities and Exchange Commission and is not intended to be and should not be used by anyone other than these specified parties.


 

 

 

/s/ KPMG LLP

 

 

 

Philadelphia, Pennsylvania
November 29, 2023